Shanghai, China – [November 10th, 2025] – Shanghai SIMR Biotechnology Co., Ltd. (“SIMR Bio” or “the Company”) announced that its novel small molecule candidate, SR2162, has received approval from the National Medical Products Administration (NMPA) to initiate clinical trials in China for the treatment of chronic pain.
The IND approval of SR2162 in China underscores SIMR Bio’s strong R&D capabilities and commitment to advancing innovative therapies for pain management. This milestone marks an important step forward in the Company’s ongoing efforts to provide safer and more effective treatment options for patients in China and around the world. Moving forward, the Company will continue to advance the clinical development of SR2162, with the goal of addressing the unmet needs of patients suffering from chronic pain and improving their quality of life.
About SR2162
SR2162 is an innovative ion channel modulator developed by SIMR Bio. Preclinical studies across multiple acute and chronic pain models have demonstrated its promising analgesic effects and potential safety advantages, suggesting SR2162 as a potential new option for the management of chronic pain.
About Chronic Pain
Chronic pain is defined as pain lasting more than three months and can significantly disrupt daily activities, including work, social interactions, and self-care. It can result from various conditions such as cancer, arthritis and nerve damage and is the leading reason for healthcare visits. Chronic pain can also contribute to anxiety, depression, and sleep disturbances, further worsening patients’ quality of life. Affecting over 30% of the global population, chronic pain remains poorly managed with existing therapies, which are often limited by inadequate efficacy and safety concerns, highlighting a substantial unmet medical need and an urgent need for safe and effective treatments.
About SIMR Bio
Founded in 2014, SIMR Bio is an innovation driven biotech company dedicated to alleviating patient suffering and improving quality of life. The Company focuses on developing novel therapies for pain, inflammation, and central nervous system disorders. SIMR Bio has established a fully integrated R&D platform spanning compound discovery, CMC research, preclinical evaluation, and clinical development. The Company’s pipeline includes multiple innovative candidates already advancing into clinical stages, demonstrating its growing global competitiveness.
